Detection and follow-up of fibroblast growth factor receptor 3 expression on bone marrow and circulating plasma cells by flow cytometry in patients with t(4;14) multiple myeloma

British Journal of Haematology

Volumn 136, Issue 4, 2007, Pages 609-614

  Chandesris, M O ^a   Soulier, J ^b   Labaume, S ^a   Crinquette, A ^b   Repellini, L ^a   Chemin, K ^a   Malphettes, M ^a,b   Fieschi, C ^a   Asli, B ^b   Uzunhan, Y ^b   Fermand, J P ^a,b   Bories, J C ^a   Arnulf, B ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

Circulating plasma cells; Fibroblast growth factor receptor 3 detection; Flow cytometry; Multiple myeloma; t(4; 14) translocation

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; SYNDECAN 1;

ADULT; ARTICLE; BONE MARROW BIOPSY; BONE MARROW CELL; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 4; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MOLECULAR CLONING; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RELIABILITY;

BONE MARROW CELLS; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 4; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM PROTEINS; PLASMA CELLS; POLYMERASE CHAIN REACTION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; TRANSLOCATION, GENETIC; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 33846424907     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2006.06479.x     Document Type: Article

References (18)

1. Chang, H., Sloan, S., Li, D., Zhuang, L., Yi, Q.L., Chen, C.I., Reece, D., Chun, K. & Stewart, A.K. (2004) The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. British Journal of Haematology, 125, 64-68.
2. Chang, H., Stewart, A.K., Qi, X.Y., Li, Z.H., Yi, Q.L & Trudel, S. (2005) Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. Blood, 106, 353-355.
3. Chen, J., Lee, B.H., Williams, I.R., Kutok, J.L., Mitsiades, C.S., Duclos, N., Cohen, S., Adelsperger, J., Okabe, R., Coburn, A., Moore, S., Huntly, B.J., Fabbro, D., Anderson, K.C., Griffin, J.D. & Gilliland, D.G. (2005) FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene, 24, 8259-8267.
4. Chesi, M., Nardini, E., Lim, R.S., Smith, K.D., Kuehl, W.M. & Bergsagel, P.L. (1998) The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IGH/MMSET hybrid transcripts. Blood, 92, 3025-3034.
5. Chesi, M., Brents, L.A., Ely, S.A., Bais, C., Robbiani, D.F., Mesri, E.A., Kuehl, W.M. & Bergsagel, P.L. (2001) Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood, 97, 729-736.
6. Dingli, D., Nowakowski, G.S., Dispenzieri, A., Lacy, M.Q., Hayman, S.R., Rajkumar, S.V., Greipp, P.R., Litzow, M.R., Gastineau, D.A., Witzig, T.E. & Gertz, M.A. (2006) Flow cytometric detection of circulating myeloma cells before transplantationin patients with multiple myeloma: a simple risk stratification system. Blood, 107, 3384-3388.
7. Jaksic, W., Trudel, S., Chang, H., Trieu, Y., Qi, X., Mikhael, J., Reece, D., Chen, C. & Stewart, A.K. (2005) Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. Journal of Clinical Oncology, 28, 7069-7073.
8. Keats, J.J., Reiman, T., Maxwell, C.A., Taylor, B.J., Larratt, L.M., Mant, M.J., Belch, A.R. & Pilarski, L.M. (2003) In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood, 101, 1520-1529.
9. Kuehl, W.M. & Bergsagel, P.L. (2005) Early genetic events provide the basis for a clinical classification of multiple myeloma. American Society of Hematology Education Program Book, 346-352.
10. L'Hôte, C.G.M. & Knowles, M.A. (2005) Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Experimental Cell Research, 304, 417-431.
11. Li, Z., Zhu, Y.X., Plowright, E.E., Bergsagel, P.L., Chesi, M., Patterson, B., Hawley, T.S., Hawley, R.G. & Stewart, A.K. (2001) The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. Blood, 97, 2413-2419.
12. Nowakowski, G.S., Witzig, T.E., Dingli, D., Tracz, M.J., Gertz, M.A., Lacy, M.Q., Lust, J.A., Dispenzieri, A., Greipp, P.R., Kyle, R.A. & Rajkumar, S.V. (2005) Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood, 106, 2276-2279.
13. Plowright, E.E., Li, Z., Bergsagel, P.L., Chesi, M., Barber, D.L., Branch, D.R., Hawley, R.G. & Stewart, A.K. (2000) Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood, 95, 992-998.
14. Rawstron, A.C., Owen, R.G., Davies, F.E., Johnson, R.J., Jones, R.A., Richards, S.J., Evans, P.A., Child, J.A., Smith, G.M., Jack, A.S. & Morgan, G.J. (1997) Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. British Journal of Haematology, 97, 46-55.
15. Santra, M., Zhan, F., Tian, E., Barlogie, B. & Shaughnessy, Jr, J. (2003) A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood, 101, 2374-2376.
16. Trudel, S., Ely, S., Farooqi, Y., Affer, M., Robbiani, D.F., Chesi, M. & Bergsagel, P.L. (2004 a) Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood, 103, 3521-3528.
17. Trudel, S., Li, Z.H., Wei, E., Wiesmann, M., Chang, H., Chen, C., Reece, D., Heise, C. & Stewart, K. (2004b) CHIR-258, a novel, multi-targeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood, 105, 2941-2948.
18. Winkler, J.M., Greipp, P.R. & Fonseca, R. (2003) t(4;14)(p16;q32) is strongly associated with a shorter survival in myeloma patients. British Journal of Haematology, 120, 170-171.